Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2002-10-14
pubmed:abstractText
Vascular endothelial growth factor (VEGF) and its receptor Flk-1/KDR play an important role in vascular permeability and tumor angiogenesis. Prompted by the hypothesis that VEGF/Flk-1 system may have regulatory roles in breast carcinogenesis, we investigated the expression of Flk-1 in 141 invasive breast carcinomas in correlation with clinical and immunohistochemical prognostic parameters, including proliferation indices like Ki-67 and Topoisomerase IIalpha (Topo-IIalpha). The immunohistochemical avidin-biotin-peroxidase method was performed on paraffin sections for the detection of Flk-1, p53, Bcl-2, c-erbB-2, Ki-67, Topo-IIalpha, ER, and PR. Flk-1 was detected in 91 of 141 (64.5%) of invasive breast carcinomas showing a widespread cytoplasmic expression in most of the neoplastic cells. Flk-1 expression was correlated with the menopausal status (P = 0.051) of the patient and the nuclear grade of the invasive breast carcinoma (P = 0.003), but demonstrated no correlation with histologic grade, stage, and patient survival. It is interesting that Flk-1 expression demonstrated a significant correlation with 2 well-established proliferation indices, Ki-67 (P = 0.037) and topo-IIalpha (P = 0.009), whereas there was no correlation with the expression of ER, PR, p53, Bcl-2, and c-erbB-2. Moreover, Flk-1 expression showed an inverse correlation with TIMP-1 mRNA localization in intratumoral stromal cells (P = 0.013). In conclusion, the significant correlation of Flk-1 expression in invasive breast carcinomas with proliferation indices like Ki-67 and topo-IIalpha suggests that VEGF may exert a growth factor activity on mammary cancer cells through its receptor Flk-1. On the other hand, the inverse correlation of Flk-1 with TIMP-1 mRNA in intratumoral stromal cells supports the notion that TIMP-1 may have an inhibitory role on angiogenesis.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type II, http://linkedlifedata.com/resource/pubmed/chemical/DNA topoisomerase II alpha, http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides..., http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vascular Endothelial..., http://linkedlifedata.com/resource/pubmed/chemical/Tissue Inhibitor of..., http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factors
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0046-8177
pubmed:author
pubmed:copyrightInfo
Copyright 2002, Elsevier Science (USA). All rights reserved.
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
863-70
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:12378509-Antigens, Neoplasm, pubmed-meshheading:12378509-Breast Neoplasms, pubmed-meshheading:12378509-Carcinoma, Ductal, Breast, pubmed-meshheading:12378509-Carcinoma, Lobular, pubmed-meshheading:12378509-Cell Division, pubmed-meshheading:12378509-Cell Nucleus, pubmed-meshheading:12378509-DNA Topoisomerases, Type II, pubmed-meshheading:12378509-DNA-Binding Proteins, pubmed-meshheading:12378509-Endothelial Growth Factors, pubmed-meshheading:12378509-Female, pubmed-meshheading:12378509-Humans, pubmed-meshheading:12378509-Immunoenzyme Techniques, pubmed-meshheading:12378509-In Situ Hybridization, pubmed-meshheading:12378509-Intercellular Signaling Peptides and Proteins, pubmed-meshheading:12378509-Ki-67 Antigen, pubmed-meshheading:12378509-Lymphokines, pubmed-meshheading:12378509-Menopause, pubmed-meshheading:12378509-RNA, Messenger, pubmed-meshheading:12378509-RNA, Neoplasm, pubmed-meshheading:12378509-Receptors, Vascular Endothelial Growth Factor, pubmed-meshheading:12378509-Survival Rate, pubmed-meshheading:12378509-Tissue Inhibitor of Metalloproteinase-1, pubmed-meshheading:12378509-Tumor Markers, Biological, pubmed-meshheading:12378509-Vascular Endothelial Growth Factor A, pubmed-meshheading:12378509-Vascular Endothelial Growth Factors
pubmed:year
2002
pubmed:articleTitle
Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
pubmed:affiliation
Department of Pathology, Medical School, University of Athens, Greece.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't